Biosimilar Development and Comparability Change Management: How to Stay Compliant

Context

Biosimilars represent a significant advancement in the pharmaceutical landscape, providing cost-effective alternatives to biologic therapies. As the biosimilar market grows, regulatory expectations become increasingly complex, particularly concerning the principles of comparability and change management. Effective navigability through these regulations is critical for Regulatory Affairs (RA), CMC (Chemistry, Manufacturing, and Controls), and Labelling teams in the US, EU, and UK. This article provides a comprehensive overview of the regulatory frameworks governing biosimilar development, focusing on the guidelines set forth by the FDA, EMA, and MHRA.

Legal/Regulatory Basis

The development of biosimilars in the US, UK, and EU is grounded in specific regulatory frameworks that vary by region. In the United States, the Biologics Control Act and the Biologics License Application (BLA) process govern the approval of biosimilars. According to Section 351(k) of the Public Health Service Act, a biological product can be deemed biosimilar to a reference product if it is shown to be highly similar, notwithstanding minor differences in clinically inactive components, and if there are no clinically meaningful differences in terms of safety, purity, and potency.

In the European Union, Regulation (EC) No 726/2004 establishes the legal basis for the approval of biosimilars under a distinct pathway within the broader biological medicinal product directive. The EMA requires the assessment of quality, safety, and efficacy to ensure that the biosimilar is comparable to its reference biologic through a rigorous comparability exercise.

The UK follows the EU model post-Brexit, with the Medicines and Healthcare products Regulatory Agency (MHRA) providing oversight aligned with EMA guidelines, but with particular emphasis on the UK’s regulatory framework for medicinal products.

Documentation

Robust documentation is essential for supporting biosimilar development and underpinning regulatory submissions. Core documentation includes:

• Comparability exercise reports: Compiling analytical, preclinical, and clinical data to demonstrate similarity to the reference product.
• Quality consistency data: Including detailed CMC information, such as manufacturing process details, quality control measures, and stability studies that confirm the biosimilar’s comparability.
• Clinical evaluation reports: Providing safety and efficacy data, including results from clinical trials specifically designed to test the biosimilar against the reference product.
• Post-market surveillance plans: Outlining how the sponsor will monitor the biosimilar’s performance and safety once it is on the market.

Review/Approval Flow

The review and approval process for biosimilars involves several key steps which vary slightly between jurisdictions:

United States

1. Pre-IND Consultation: Engaging with the FDA early to discuss development plans.
2. Investigational New Drug Application (IND): Filing before initiating clinical trials, with sufficient data on drug manufacturing and proposed clinical study protocols.
3. Biosimilar Application (BLA): Submission involving CMC, clinical, and immunogenicity data reflective of the biosimilar’s similarity to the reference product.
4. FDA Review: The FDA conducts a thorough evaluation, focusing on manufacturing processes, clinical data, proposed labeling, and post-market safety protocols.
5. Approval and Post-Marketing Surveillance: Following approval, ongoing monitoring and adverse event reporting systems will be implemented.

European Union

1. Pre-submission Meetings: Interaction with the EMA to clarify expectations and receive guidance on necessary data submission.
2. Marketing Authorization Application (MAA): Comprehensive submission including all data supporting biosimilarity.
3. Scientific Advice: Potential interaction with EMA regarding specific queries during the review process.
4. EMA Evaluation: Involves an in-depth scientific assessment of the quality, preclinical, and clinical data.
5. Post-Authorization Safety Studies (PASS): Ongoing studies mandated to evaluate long-term safety and effectiveness.

United Kingdom

1. Early Engagement: Advisable interaction with MHRA for preliminary feedback.
2. Clinical Trial Authorization (CTA): Necessary for conducting clinical trials comparable to referenced therapies.
3. Marketing Authorisation Application (MAA): Submission comprising CMC and nonclinical data similar to EU MA plan.
4. MHRA Review: Evaluation focusing on risk assessments, comparability data, and public health considerations.
5. Ongoing Safety Monitoring: Requirement for risk management plans and adherence to pharmacovigilance obligations.

Common Deficiencies

During biosimilar development, several common deficiencies can arise that may lead to approval delays or additional requests for information from regulatory authorities:

• Insufficient Comparability Data: If the data fails to demonstrate that the biosimilar is highly similar to the reference product, including inadequate analytical assessment results.
• Clinical Study Design Flaws: Deficiencies in clinical trial design, including inappropriate endpoints or lack of robust controls, can lead to rejection of applications.
• Poor Quality Information: Incomplete or inconsistent CMC documentation or failure to address process changes during manufacturing can raise significant concerns.
• Deficient Risk Management Plans: Inability to provide sufficient plans for post-marketing surveillance of safety issues and potential adverse event reporting may trigger scrutiny.

RA-Specific Decision Points

When to File as a Variation vs. New Application

The decision to file for a variation or a new application hinges on the scope and nature of the changes being made to an existing biosimilar product:

• File as a Variation: When modifications pertain to manufacturing processes, formulation adjustments, or labeling changes that do not alter the core product identity or its reason for approval.
• File as a New Application: If changes include significant alterations to the clinical presentation, such as introducing a new indication, a new strength, or a significant alteration in the active substance that impacts safety or efficacy.

How to Justify Bridging Data

Justifying the use of bridging data is critical when expediting the regulatory process. Bridging studies are designed to demonstrate the comparability of two different production processes or formulations. Key points for effective justification include:

• Data Consistency: Use consistent datasets during the development phase to establish a valid comparability exercise.
• Regulatory Guidance Compliance: Align bridging data with specific guidance documents from authorities such as the FDA’s “Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product” or the EMA’s “Guideline on similar biological medicinal products”.
• Comprehensive Analytical Assessment: Provide a thorough analytical characterization that underlines the similarities and addresses any biochemical or biophysical differences observed.

Conclusion

In summary, biosimilar development in the context of regulatory compliance poses unique challenges and demands deep understanding of varied regulatory expectations across regions. Regulatory Affairs teams must be vigilant in their approach to documenting comparability, engaging with regulatory authorities throughout the approval process, and addressing potential deficiencies proactively. By systematically navigating the guidelines set forth by the FDA, EMA, and MHRA, and employing thorough documentation practices, the progression from development to market approval can be effectively managed.

For further guidance, it is recommended to refer to the official resources provided by organizations such as EMA, FDA, and MHRA to ensure the latest updates and requirements are consistently integrated into biosimilar development strategies.